Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Visiongain new report: Global anti obesity drugs market forecast 2018-2028

3 views

Published on

Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Visiongain new report: Global anti obesity drugs market forecast 2018-2028

  1. 1. / Page 86visiongain.com/industries/pharma Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs cholecystokinin and peptide YY etc. have further strengthened the forecasted growth arte of this market. Table 4.13 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%), CAGR (%) 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Others (Revenue, $m) 73 101 133 194 292 448 680 1,037 1,577 2,438 3,812 5,904 AGR (%) 34.5% 37.8% 32.0% 46.0% 50.7% 53.2% 52.0% 52.4% 52.0% 54.6% 56.4% 54.9% CAGR (%, 2017-22 & 2023-28) 43.7 53.4 CAGR (%, 2017- 27) 48.9 Source: Visiongain 2018 Figure 4.17 Global Anti-obesity Other Drugs Market 2017-2028: Revenue ($m), AGR (%) Source: Visiongain 2018 0% 10% 20% 30% 40% 50% 60% - 1,000 2,000 3,000 4,000 5,000 6,000 7,000 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 AGR,% Revenue,$m Year
  2. 2. / Page 134visiongain.com/industries/pharma Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs Table 5.9 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%), CAGR (%) 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 Revenue, $m 86 93 115 142 179 225 292 386 515 690 927 1,249 AGR (%) 9.0% 23.1% 24.1% 25.5% 26.1% 29.5% 32.5% 33.3% 34.0% 34.3% 34.8% CAGR (%, 2017-22 & 2023-28) 21.4 33.8 CAGR (%, 2017-28) 27.6 Source: Visiongain 2018 Figure 5.17 Qysmia Sales Forecast 2017-2028: Revenue ($m), AGR (%) Source: Visiongain 2018 0% 5% 10% 15% 20% 25% 30% 35% 40% - 200 400 600 800 1,000 1,200 1,400 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 AGR,% Revenue,$m
  3. 3. / Page 200visiongain.com/industries/pharma Global Anti-obesity Drugs Market Forecast 2018-2028: Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs In the global market, market share of China, India, Brazil, and Russia are expected to be 7.7%, 5.8%, 2.9%, and 1.1%, respectively, by 2028. Amongst the BRIC countries, the market share of China, India, Brazil, and Russia are 43.8%, 33.3%, 16.8%, and 6.1%, respectively by 2028. Figure 6.33 BRIC Anti-obesity Drugs Market Forecast by Region: Global Market Share (%), 2028 Source: Visiongain 2018 Figure 6.34 BRIC Anti-obesity Drugs Market Forecast by Region: Market Share (%), 2017 Source: Visiongain 2018 US 51.4% EU5 13.6% Japan 3.6% RoW 13.9% China 7.7% India 5.8% Brazil 2.9% Russia 1.1% BRIC 8.3% 38.4% 32.5% 19.5% 9.6% China India Brazil Russia

×